Agritek Holdings Inc. (AGTK)

[81vette]

Biomedican generates cannabinoids and terpenes directly from proprietary yeast without costly plant cultivation or inefficient extraction and purification procedures in a scalable fashion. Production facilities for biosynthesis cost a fraction of traditional cannabis facilities enabling much more cost-efficient manufacturing.



Biomedican research and production strategies are continuously improving. Our intellectual property portfolio keeps growing as we aim to streamline the production pipeline of pure and consistent compounds that are in high demand across many regions in the U.S. and Canada.



Investors benefit from the ability to participate in an industry currently gaining enormous momentum. Our proprietary technology can revolutionize the cannabinoid supply chain and directly feed into several markets where cannabinoids and terpenes are in high demand. As the production of cannabinoids and terpenes through biosynthesis is significantly quicker than traditional methods, investors can expect a faster return on investments.